Company announced new financing yesterday and the share price took a hit to below six cents.
The company now has operating capital for the next 18 months.
An anticipated deal with Becton Dickinson will move the share price above .50.
The company's patented MANF drug could also be worth billions of dollars.
Follow the company on Twitter: @AmarantusBio 8,430 followers